Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Approves First Coronavirus Drugs, Rushes Two Vaccine Trials

Can China Ace The Race?

Executive Summary

A coronavirus vaccine race is on in China with three domestic developers leading the charge, while traditional medicines are pioneering the drug race after the first official approvals of treatments for COVID-19.

You may also be interested in...



As China Promotes TCMs, Ban Against Criticizing The Remedies Proposed In Beijing Province

In a key step to prop up traditional Chinese medicines, Beijing has proposed a law that could potentially punish any vocal doubters. The move signals a familiar pattern as China resorts to using old approaches when facing a flurry of new challenges.

As China Glorifies Traditional Medicines, Doubters See A Haunted Past

In a key step to prop up traditional Chinese medicines, Beijing has proposed a law that could potentially punish any vocal doubters. The move signals a familiar pattern as China resorts to using old approaches when facing a flurry of new challenges.

China, US Carve Own Paths But Physicians Urge Collaboration With Vaccines Years Away

Despite different approaches, top virologists and renowned front-line physicians from China and the US see the need to share clinical experiences and for global cooperation on treatments and vaccines as economies start re-opening amid fear of a second wave. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel